---
title: "Varegacestat (AL102) in Desmoid tumors: Pharmacodynamics"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Pharmacodynamics. Topics: Notch target gene inhibition in peripheral blood, Exposure-response for efficacy in RINGSIDE, Exposure-response for safety in a pooled phase 1 to phase 3 population, Exposure-response modeling of tumor volume and dose selection, and 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Notch target gene inhibition in peripheral blood

> “Target inhibition of Notch pathway related genes was observed.”
> “Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.”
> “After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2).”
> “At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.6.2-2"></a>

### Exposure-response for efficacy in RINGSIDE

> “This analysis aimed to characterize the relationship between VAR plasma exposure and selected efficacy endpoints in patients with progressing desmoid tumors (DTs) and safety endpoints in patients with advanced solid tumors (ASTs) and DTs.”
> “Efficacy analysis included 198 participants from Ph2/3 RINGSIDE study (DT):”
> “Although exposure was not a statistically significant predictor of PFS and ORR, increasing trends were observed in ORR, TTV, and SLD with increasing VAR Cavg, supporting maximal efficacy at 1.2 mg QD.”
> “Trend toward increase in ORR with higher VAR Cavg, however not statistically significant (p = 0.0818).”
> “Trend toward decreasing ORR with lower starting dose compared to 1.2 mg QD.”
> “At 1.2 mg QD, TGI models predicted greater target attainment at Week 48 compared to 0.9 mg QD.”
> “Dose reduction had no apparent impact on PFS.”
> “No impact of dose reductions on TTV/SLD.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### Exposure-response for safety in a pooled phase 1 to phase 3 population

> “Safety analysis included 157 participants treated with VAR:”
> “36 from Ph1 Study CA002001 (solid tumors).”
> “Identified statistically significant (p < 0.05) ER relationships for VAR Cavg and the endpoints TESAEs, Grade 2+ TEAEs: nausea/vomiting, fatigue, diarrhea, hypophosphatemia and rash. No statistically significant relationship was observed between VAR exposure and Grade 2+ ALT elevation and ovarian toxicity.”
> “Safety ER models predicted no clinically meaningful reduction in AE rates at reduced starting doses of 0.9 or 0.6 mg QD.”
> “In clinical studies, dose modifications including dose reductions, were effective in managing these AEs.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

| Adverse event of interest | Incidence, n (%) |
| --- | --- |
| Treatment-emergent serious adverse events | “49 (31.2)” |
| Grade 2+ hypophosphatemia | “47 (29.9)” |
| Grade 2+ fatigue | “43 (27.4)” |
| Grade 2+ nausea/vomiting | “31 (19.7)” |
| Grade 2+ diarrhea | “59 (37.6)” |
| Ovarian toxicity | “32 (50.0)” |
| Grade 2+ rash | “58 (36.9)” |
| Grade 2+ ALT elevation | “9 (5.7)” |
| Note | “Safety analysis population count was (N = 157) for all endpoints except ovarian toxicity (N = 64).” |

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### Exposure-response modeling of tumor volume and dose selection

> “Exposure-response modeling evaluated time course of drug effect on tumor volume to support selection of 1.2 mg once daily for further study”
> “Exploratory exposure-response modelling suggested that 1.2 mg once daily dose achieves earlier and deeper response than the other dose regimens”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Nonclinical pharmacology and toxicology

> “Nonclinical experiments showed that BMS-986115 was effective as a single agent in the treatment of human T-ALL xenograft models, and demonstrated anti-tumour activity against 5 out of 7 solid tumour xenografts evaluated, including 3 breast, 1 NSCLC, and 1 pancreatic carcinoma. In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation. Notch inhibitor mediated GI toxicity, which is characterized by goblet cell metaplasia throughout the intestines, is the result of on-target drug-induced differentiation of small intestinal and colonic progenitors to the secretory (goblet) cell fate.”
> “Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
